文献速递肝病

贝扎贝特改善原发性胆汁性胆管炎患者的GLOBE和UK-PBC评分及长期结局

Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.
PubMed 文献 · Hepatology · 2019-04-12

日本PBC研究组回顾性队列(n=873)中纳入118例接受UDCA单药治疗至少1年、随后UDCA+贝扎贝特联合治疗至少1年的患者;联合治疗1年后GLOBE评分从0.504±0.080显著降至0.115±0.085(P<0.0001),真实无肝移植生存优于贝扎贝特引入前GLOBE评分预测值;结论认为加用贝扎贝特改善GLOBE和UK-PBC评分及长期预后,尤其早期PBC患者。

要点

  • UDCA+贝扎贝特联合治疗1年使GLOBE评分从0.504±0.080显著降至0.115±0.085(P<0.0001)。
  • 真实无肝移植生存显著优于贝扎贝特引入前GLOBE评分预测值。
  • UDCA单药1年后血清胆红素正常者加用贝扎贝特,调整HR 0.09(95%CI 0.01-0.60,P=0.013)。

核心结论

  • 在UDCA单药治疗基础上加用贝扎贝特不仅改善GLOBE和UK-PBC评分,也改善PBC患者长期预后,尤其是早期PBC患者。

研究设计与样本

  • 日本PBC研究组的回顾性队列(n=873)中纳入118例接受UDCA单药治疗至少1年、随后UDCA+贝扎贝特联合治疗至少1年的患者。
  • 比较UDCA单药治疗后(即UDCA+贝扎贝特联合治疗前)与联合治疗1年后的GLOBE和UK-PBC评分。
  • 采用Kaplan-Meier分析估计真实结局并与GLOBE和UK-PBC评分预测结局比较,采用倾向性评分分析计算贝扎贝特治疗的风险比。

主要发现

  • 联合治疗前平均GLOBE评分为0.504±0.080,联合治疗1年后显著改善至0.115±0.085(P<0.0001)。
  • 入组患者真实无肝移植生存显著优于贝扎贝特引入前GLOBE评分预测值。
  • 与贝扎贝特引入前UK-PBC风险评分预测值相比,联合治疗未显著改善真实肝移植或肝相关死亡发生率,但加用贝扎贝特后预测风险显著降低(P<0.0001)。
  • 采用逆概率治疗加权的Cox回归分析显示,UDCA单药治疗1年后血清胆红素正常的患者加用贝扎贝特显著降低肝移植或肝相关死亡风险(调整风险比0.09,95%置信区间0.01-0.60,P=0.013)。

临床怎么用

  • 作者认为,在UDCA单药治疗基础上加用贝扎贝特可改善GLOBE和UK-PBC评分及长期预后,尤其是早期PBC患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In Japan, bezafibrate (BF) is a second-line agent for primary biliary cholangitis (PBC) that is refractory to ursodeoxycholic acid (UDCA) treatment. From a retrospective cohort (n = 873) from the Japan PBC Study Group, we enrolled 118 patients who had received UDCA monotherapy for at least 1 year followed by combination therapy with UDCA+BF for at least 1 year. GLOBE and UK-PBC scores after UDCA monotherapy (i.e., immediately before UDCA+BF combination therapy) were compared with those after 1 year of UDCA+BF combination therapy. The real outcomes of enrolled patients estimated by Kaplan-Meier analysis were compared with the predicted outcomes calculated using GLOBE and UK-PBC scores. In addition, the hazard ratio of BF treatment was calculated using propensity score analysis. The mean GLOBE score before the combination therapy was 0.504 ± 0.080, which improved significantly to 0.115 ± 0.085 (P < 0.0001) after 1 year of combination therapy. The real liver transplant-free survival of enrolled patients was significantly better than that predicted by GLOBE score before introducing BF. Combination therapy did not significantly improve the real rates of liver transplantation or liver-related death compared with those predicted by UK-PBC risk score before introducing BF, but the predicted risk was significantly reduced by the addition of BF (P < 0.0001). Cox regression analysis with inverse probability of treatment weighting showed that the addition of BF significantly reduced the hazard of liver transplant or liver-related death in patients who, after 1 year of UDCA monotherapy, had normal serum bilirubin (adjusted hazard ratio 0.09, 95% confidence interval 0.01-0.60, P = 0.013). Conclusion: Addition of BF to UDCA monotherapy improves not only GLOBE and UK-PBC scores but also the long-term prognosis of PBC patients, especially those with early-stage PBC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Honda A, Tanaka A, Kaneko T, et al. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis. Hepatology. 2019. PMID: 30737815. doi:10.1002/hep.30552

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。